NCT02806219 - Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Healthy

Interventions

DEVICE

Prefilled syringe (PFS)

Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)

DEVICE

e-Device

Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device

Trial Locations (1)

Ra0132 001, Baltimore